Venue: 10F 10A

Research program in IgAN : Towards personalized risk based management of IgAN

Chair

Yusuke Suzuki

Speaker

Sean Barbour

Venue: 3F KFC Hall

IgA Nephropathy: Where we are and where we are going

Chair

Adrien Liew

Speaker

Hernán Trimarchi

Symposium Overview:

• Title “IgA Nephropathy: Where we are and where we are going”
• Learning Objectives:

  1. Uncover the complexity of IgAN diagnosis, management, and challenges from a clinician perspective.

  2. Review the pathogenesis of IgAN along with the role of the Endothelin and APRIL pathways in IgAN.

Venue: 2F KFC Hall 2nd

IgA nephropathy: Insights into pathogenesis and clinical challenges

Moderator

Heather N. Reich

Pathogenesis of IgA nephropathy: Current understanding

Speaker

Sydney Tang

Heterogeneity in clinical presentation and progression of IgA nephropathy

Speaker

Dana Rizk

The challenges with IgA nephropathy in clinical practice: Insights from real-world data

Speaker

Hong Zhang

Symposium Overview

Venue: 3F KFC Hall

Evolving landscape in IgAN – Treating IgAN in 2023 and Beyond

Moderator

Yusuke Suzuki

Redefining Standards for IgAN Treatment in a Rapidly Evolving Landscape

Speaker

Jonathan Barratt

IgAN Treatment: a clinical update

Speaker

Richard Lafayette

Symposium Overview

Venue: 2F KFC hall 2nd

How should we treat anemia in CKD patients to maximize their well-being?

Chair

Kunihiro Yamagata

Speaker

Takehiko Wada

Symposium Overview:

Anemia in chronic kidney disease (CKD) patients is known to be associated with a high burden of morbidity and adverse clinical outcomes. While the role of anemia in patient outcomes specific to IgA nephropathy, as the primary disease, has yet to be established, several studies have suggested its association with worse outcomes. On the other hand, there is currently no consensus on the optimal degree of anemia improvement or the appropriate treatment approach.
This presentation aims to share the current knowledge on the significance of anemia and to discuss optimal therapeutic approaches to maximize the well-being of CKD patients.

Venue: 3F KFC Hall

Understanding the Role of APRIL in the Pathogenesis of IgA Nephropathy

Moderator

Yusuke Suzuki

Speaker

Dana Rizk, Yoshihito Nihei

Symposium Objectives:

• Review background on IgA Nephropathy
  and the four-hit IgA Nephropathy pathogenesis
• Discuss B-cell biology and review for APRIL physiologic roles
• Review scientific evidence that supports the role of APRIL in IgA Nephropathy pathogenesis

Venue: 2F KFC hall 2nd

Global Diversity and Controversies in IgA Nephropathy: A Conversation with Experts

Moderator

Jonathan Barratt

Speaker

Heather N. Reich, Hernán Trimarchi, Suceena Alexander

Symposium Overview

Venue: 2F KFC hall 2nd

SGLT2: Old yet New

Chair

Ichiei Narita

Speaker

Eisei Sohara

Symposium Overview:

SGLT (Sodium Glucose co-transporter) is a transporter for glucose reabsorption in the renal proximal tubules. It has been considered to be important for energy retention in the body, and SGLT mutations were found to cause “Renal Glucosuria”. After a period of decades, SGLT2 inhibitors have recently gained attention for their therapeutic application in the treatment of CKD. In this seminar, I would like to give an overview of this old and new SGLT2 and its inhibitors from the viewpoints of genetics, physiology, and clinical nephrology.

Venue: 2F KFC hall 2nd

Targeting the Source of IgA Nephropathy
The Potential Role of BLyS and APRIL in the Pathogenesis of IgA Nephropathy: Implications for Dual Inhibition

Speaker

Chee Kay Cheung

Emerging Therapies in IgA Nephropathy: Targeted Mechanisms and Clinical Implications

Speaker

Richard Lafayette

Symposium Overview:

IgAN is a serious and progressive autoimmune disease of the kidney, for which there remains a high unmet medical need. The 4-hit mechanism establishes that abnormal accumulation of Gd-IgA1 is the instigating process in IgAN, leading to the expression of anti-Gd-IgA1 antibodies and eventually immune complex formation and deposition in the glomerulus. B-cell differentiation and survival are critical to the formation of Gd-IgA1, and these processes are in turn driven by the cytokines BLyS (B lymphocyte stimulator) and APRIL (a proliferation-inducing ligand). By inhibiting the function of BLyS and APRIL, the disease process is targeted early in its pathogenesis.
In this symposium, we will review the immune mechanisms at the source of IgAN and describe how therapies targeting BLyS and APRIL reduce proteinuria and may preserve eGFR. We will also familiarize the audience with the growing understanding of BLyS/APRIL biology in health and disease.

Venue: 3F KFC Hall

Biological responses induced by SGLT2 inhibitors

Chair

Yoshitaka Isaka

Speaker

Akira Nishiyama

Symposium Overview:

SGLT2 inhibitors have been reported to reduce cardiovascular and renal risks in patients with Type 2 diabetes, in addition to their primary function of lowering blood glucose levels. We conducted a basic analysis of the pharmacological mechanisms of action of SGLT2 inhibitors and demonstrated that they induce transient diuresis accompanied by an increase in urinary glucose. SGLT2 inhibitors also have an influence on blood pressure, accompanied by a decrease in sympathetic nerve activity, and exert an influence on ischemia by reducing renal interstitial glucose concentration. Furthermore, a series of adaptive responses are triggered to compensate for the energy and water loss caused by SGLT2 inhibitors. These responses are similar to the "aestivation-like response" that we recently discovered and may exert an influence on organs.

Venue: 2F KFC hall 2nd

A new insight into the treatment of anemia in chronic kidney disease

Chair

Takashi Yokoo

Speaker

Hiroshi Nishi

Symposium Overview:

The cause of anemia in chronic kidney disease is the relative inadequacy of supply to hematopoietic demand due to impaired production of erythropoietin associated with impaired renal function. The mainstays of anemia treatment are erythropoietin stimulating agents and adequate iron supplementation. In particular, the advent of hypoxia-inducible factor prolyl hydroxylase inhibitors in the past few years has revolutionized our understanding of the pathogenesis of anemia, pharmacological treatment strategy, and the physician-patient relationship. The current understanding and applications of those treatments will be outlined from both basic and clinical viewpoints.